Business
BioElectronics Presents FDA Reclassification Panel
BioElectronics Presents FDA Reclassification Panel.
About this update from Bioelectronics Corp.
[{"type":"text","content":"\n\n\n\n\n\n\n\nBioElectronics Presents FDA Reclassification Panel\n\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:\"0in\";\n}\n\n\n\n\n\n\n\n\n\n\nBioElectronics Presents FDA Reclassification Panel\n\nConfirmation of Physiological Mechanism for Pain Relief\n\nPR Newswire\n\nFREDERICK, Md., May 21, 2013\n\n\n\n\n\n\n\nFREDERICK, Md., May 21, 2013 /PRNewswire/ -- BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free consumer electronic devices, announced that CEO, Andrew J. Whelan is presenting today to the FDA's Medical Advisory Committee, Orthopedic and Rehabilitation Panel compelling arguments for reclassifying the company's products for over the counter sales.\n\n\n\"It's been 37 years since the FDA developed its medical device classification schema,\" Whelan said. \"While the old classification of pulsed shortwave devices probably made sense in the 1970s, it is out of date in light of the dramatic advances in research and it would be lamentable if U.S. consumers were denied access to this safe, drug-free and cost-effective technology.\" \n\n\nWhelan attributed the FDA classification decision to a lack of an understandable mechanism of action of pulsed shortwave technology at that time. \"While pulsed shortwave diathermy has been in use for more than 80 years using large, high-voltage, clinic-based machines and is routinely used in the United Kingdom in 11% of all physical therapy sessions,\" Whelan explained. \"The safety record is unassailable.\" The FDA's own executive summary prepared for the meeting reported that in more than 17 years of its record keeping there were only 5 reports of adverse effects from any of these systems, (including high power systems) none of which were life-threatening or could be attributed to the devices.[i] \n\n\n\"We've sold hundreds of thousands of our miniature, low-power devices and have never had an adverse effect reported.\" Whelan said. Nonetheless, in the absence of a clear demonstration of a mechanism of action, the FDA was put in a position of having to class...